Eli Lilly, a prominent U.S. pharmaceutical company, has forged a partnership with NVIDIA to establish the inaugural supercomputer globally, which is both owned and operated by a pharmaceutical enterprise. This cutting-edge system harnesses the power of more than 1,000 NVIDIA DGX B300 GPUs and is founded on a cohesive network architecture to amplify operational efficiency. It propels an 'AI factory' that is adept at swift self-learning and continual refinement. Scientists can utilize this platform to train AI models and evaluate potential drug candidates. Furthermore, Eli Lilly offers exclusive access to certain proprietary models via its Lilly TuneLab platform. Beyond this, Eli Lilly envisions leveraging this advanced technology to condense drug development timelines, expedite the introduction of novel drugs, aid researchers, facilitate personalized treatment approaches, enhance manufacturing productivity, and curtail downtime.